Neoadjuvant  ||| S:0 E:12 ||| NNP
and  ||| S:12 E:16 ||| CC
adjuvant  ||| S:16 E:25 ||| JJ
strategies  ||| S:25 E:36 ||| NNS
in  ||| S:36 E:39 ||| IN
renal  ||| S:39 E:45 ||| JJ
cell  ||| S:45 E:50 ||| NN
carcinoma ||| S:50 E:59 ||| NNS
:  ||| S:59 E:61 ||| :
more  ||| S:61 E:66 ||| JJR
questions  ||| S:66 E:76 ||| NNS
than  ||| S:76 E:81 ||| IN
answers  ||| S:81 E:89 ||| NNS
The  ||| S:89 E:93 ||| DT
current  ||| S:93 E:101 ||| JJ
standard  ||| S:101 E:110 ||| JJ
treatment  ||| S:110 E:120 ||| NN
for  ||| S:120 E:124 ||| IN
early  ||| S:124 E:130 ||| JJ
stage  ||| S:130 E:136 ||| NN
( ||| S:136 E:137 ||| -LRB-
I-III ||| S:137 E:142 ||| NNP
)  ||| S:142 E:144 ||| -RRB-
renal  ||| S:144 E:150 ||| JJ
cell  ||| S:150 E:155 ||| NN
cancer  ||| S:155 E:162 ||| NN
( ||| S:162 E:163 ||| -LRB-
RCC ||| S:163 E:166 ||| NNP
)  ||| S:166 E:168 ||| -RRB-
is  ||| S:168 E:171 ||| VBZ
surgery ||| S:171 E:178 ||| NN
.  ||| S:178 E:180 ||| .
While  ||| S:180 E:186 ||| IN
the  ||| S:186 E:190 ||| DT
prognosis  ||| S:190 E:200 ||| NN
of  ||| S:200 E:203 ||| IN
stage  ||| S:203 E:209 ||| NN
I  ||| S:209 E:211 ||| PRP
tumors  ||| S:211 E:218 ||| RB
is  ||| S:218 E:221 ||| VBZ
excellent ||| S:221 E:230 ||| JJ
,  ||| S:230 E:232 ||| ,
stage  ||| S:232 E:238 ||| NN
II  ||| S:238 E:241 ||| NNP
and  ||| S:241 E:245 ||| CC
particularly  ||| S:245 E:258 ||| RB
stage  ||| S:258 E:264 ||| VB
III  ||| S:264 E:268 ||| NNP
have  ||| S:268 E:273 ||| VBP
a  ||| S:273 E:275 ||| DT
high  ||| S:275 E:280 ||| JJ
risk  ||| S:280 E:285 ||| NN
of  ||| S:285 E:288 ||| IN
relapse ||| S:288 E:295 ||| NN
.  ||| S:295 E:297 ||| .
The  ||| S:297 E:301 ||| DT
adjuvant  ||| S:301 E:310 ||| JJ
treatment  ||| S:310 E:320 ||| NN
of  ||| S:320 E:323 ||| IN
patients  ||| S:323 E:332 ||| NNS
with  ||| S:332 E:337 ||| IN
RCC  ||| S:337 E:341 ||| NNP
remains  ||| S:341 E:349 ||| VBZ
an  ||| S:349 E:352 ||| DT
area  ||| S:352 E:357 ||| NN
of  ||| S:357 E:360 ||| IN
investigation ||| S:360 E:373 ||| NN
,  ||| S:373 E:375 ||| ,
with  ||| S:375 E:380 ||| IN
patient  ||| S:380 E:388 ||| JJ
selection  ||| S:388 E:398 ||| NN
being  ||| S:398 E:404 ||| VBG
a  ||| S:404 E:406 ||| DT
key  ||| S:406 E:410 ||| JJ
aspect ||| S:410 E:416 ||| NN
.  ||| S:416 E:418 ||| .
There  ||| S:418 E:424 ||| EX
are  ||| S:424 E:428 ||| VBP
currently  ||| S:428 E:438 ||| RB
two  ||| S:438 E:442 ||| CD
prognostic  ||| S:442 E:453 ||| JJ
nomograms  ||| S:453 E:463 ||| NN
to  ||| S:463 E:466 ||| TO
establish  ||| S:466 E:476 ||| VB
the  ||| S:476 E:480 ||| DT
risk  ||| S:480 E:485 ||| NN
of  ||| S:485 E:488 ||| IN
relapse  ||| S:488 E:496 ||| NN
in  ||| S:496 E:499 ||| IN
patients  ||| S:499 E:508 ||| NNS
with  ||| S:508 E:513 ||| IN
resected  ||| S:513 E:522 ||| JJ
RCC ||| S:522 E:525 ||| NNP
.  ||| S:525 E:527 ||| .
The  ||| S:527 E:531 ||| DT
results  ||| S:531 E:539 ||| NNS
of  ||| S:539 E:542 ||| IN
earlier  ||| S:542 E:550 ||| JJR
studies  ||| S:550 E:558 ||| NNS
of  ||| S:558 E:561 ||| IN
adjuvant  ||| S:561 E:570 ||| JJ
therapy ||| S:570 E:577 ||| NN
,  ||| S:577 E:579 ||| ,
including  ||| S:579 E:589 ||| VBG
the  ||| S:589 E:593 ||| DT
use  ||| S:593 E:597 ||| NN
chemotherapy  ||| S:597 E:610 ||| NNS
and ||| S:610 E:613 ||| CC
/ ||| S:613 E:614 ||| NNP
or  ||| S:614 E:617 ||| CC
immunotherapy  ||| S:617 E:631 ||| NN
after  ||| S:631 E:637 ||| IN
nephrectomy  ||| S:637 E:649 ||| NNS
have  ||| S:649 E:654 ||| VBP
failed  ||| S:654 E:661 ||| VBN
to  ||| S:661 E:664 ||| TO
show  ||| S:664 E:669 ||| VB
any  ||| S:669 E:673 ||| DT
benefit  ||| S:673 E:681 ||| NN
in  ||| S:681 E:684 ||| IN
the  ||| S:684 E:688 ||| DT
outcome  ||| S:688 E:696 ||| NN
of  ||| S:696 E:699 ||| IN
patients  ||| S:699 E:708 ||| NNS
at  ||| S:708 E:711 ||| IN
risk  ||| S:711 E:716 ||| NN
of  ||| S:716 E:719 ||| IN
developing  ||| S:719 E:730 ||| VBG
local  ||| S:730 E:736 ||| JJ
recurrence  ||| S:736 E:747 ||| NN
or  ||| S:747 E:750 ||| CC
distant  ||| S:750 E:758 ||| JJ
metastases ||| S:758 E:768 ||| NN
.  ||| S:768 E:770 ||| .
Two  ||| S:770 E:774 ||| CD
recent  ||| S:774 E:781 ||| JJ
phase  ||| S:781 E:787 ||| NN
III  ||| S:787 E:791 ||| NNP
trials  ||| S:791 E:798 ||| NNS
with  ||| S:798 E:803 ||| IN
vaccines  ||| S:803 E:812 ||| NNS
( ||| S:812 E:813 ||| -LRB-
autologous  ||| S:813 E:824 ||| JJ
tumor  ||| S:824 E:830 ||| NN
cell  ||| S:830 E:835 ||| NN
vaccine  ||| S:835 E:843 ||| NN
and  ||| S:843 E:847 ||| CC
autologous  ||| S:847 E:858 ||| JJ
tumor-derived  ||| S:858 E:872 ||| JJ
heat  ||| S:872 E:877 ||| NN
shock  ||| S:877 E:883 ||| NN
protein  ||| S:883 E:891 ||| NN
peptide  ||| S:891 E:899 ||| VBD
complex-96 ||| S:899 E:909 ||| CD
)  ||| S:909 E:911 ||| -RRB-
have  ||| S:911 E:916 ||| VBP
shown  ||| S:916 E:922 ||| VBN
promising ||| S:922 E:931 ||| JJ
,  ||| S:931 E:933 ||| ,
albeit  ||| S:933 E:940 ||| IN
still  ||| S:940 E:946 ||| RB
preliminary ||| S:946 E:957 ||| JJ
,  ||| S:957 E:959 ||| ,
results ||| S:959 E:966 ||| NNS
.  ||| S:966 E:968 ||| .
In  ||| S:968 E:971 ||| IN
the  ||| S:971 E:975 ||| DT
metastatic  ||| S:975 E:986 ||| JJ
RCC  ||| S:986 E:990 ||| NNP
setting ||| S:990 E:997 ||| NN
,  ||| S:997 E:999 ||| ,
recent  ||| S:999 E:1006 ||| JJ
advances  ||| S:1006 E:1015 ||| NNS
in  ||| S:1015 E:1018 ||| IN
the  ||| S:1018 E:1022 ||| DT
molecular  ||| S:1022 E:1032 ||| JJ
understanding  ||| S:1032 E:1046 ||| NN
of  ||| S:1046 E:1049 ||| IN
oncogenic  ||| S:1049 E:1059 ||| JJ
pathways  ||| S:1059 E:1068 ||| NNS
have  ||| S:1068 E:1073 ||| VBP
led  ||| S:1073 E:1077 ||| VBN
to  ||| S:1077 E:1080 ||| TO
the  ||| S:1080 E:1084 ||| DT
development  ||| S:1084 E:1096 ||| NN
of  ||| S:1096 E:1099 ||| IN
new  ||| S:1099 E:1103 ||| JJ
therapeutic  ||| S:1103 E:1115 ||| JJ
strategies  ||| S:1115 E:1126 ||| NNS
with  ||| S:1126 E:1131 ||| IN
the  ||| S:1131 E:1135 ||| DT
use  ||| S:1135 E:1139 ||| NN
of  ||| S:1139 E:1142 ||| IN
targeted  ||| S:1142 E:1151 ||| JJ
therapies  ||| S:1151 E:1161 ||| NNS
in  ||| S:1161 E:1164 ||| IN
the  ||| S:1164 E:1168 ||| DT
adjuvant  ||| S:1168 E:1177 ||| JJ
setting ||| S:1177 E:1184 ||| NN
.  ||| S:1184 E:1186 ||| .
Neoadjuvant  ||| S:1186 E:1198 ||| JJ
treatment  ||| S:1198 E:1208 ||| NN
is  ||| S:1208 E:1211 ||| VBZ
another  ||| S:1211 E:1219 ||| DT
treatment  ||| S:1219 E:1229 ||| NN
modality  ||| S:1229 E:1238 ||| VBZ
currently  ||| S:1238 E:1248 ||| RB
being  ||| S:1248 E:1254 ||| VBG
evaluated  ||| S:1254 E:1264 ||| VBN
for  ||| S:1264 E:1268 ||| IN
patients  ||| S:1268 E:1277 ||| NNS
with  ||| S:1277 E:1282 ||| IN
early  ||| S:1282 E:1288 ||| JJ
disease  ||| S:1288 E:1296 ||| NN
and  ||| S:1296 E:1300 ||| CC
in  ||| S:1300 E:1303 ||| IN
patients  ||| S:1303 E:1312 ||| NNS
with  ||| S:1312 E:1317 ||| IN
metastatic  ||| S:1317 E:1328 ||| JJ
RCC  ||| S:1328 E:1332 ||| NN
with  ||| S:1332 E:1337 ||| IN
inoperable  ||| S:1337 E:1348 ||| JJ
primary  ||| S:1348 E:1356 ||| JJ
tumors ||| S:1356 E:1362 ||| NNS
.  ||| S:1362 E:1364 ||| .
The  ||| S:1364 E:1368 ||| DT
questions  ||| S:1368 E:1378 ||| NNS
that  ||| S:1378 E:1383 ||| WDT
remain  ||| S:1383 E:1390 ||| VBP
unanswered  ||| S:1390 E:1401 ||| RB
include  ||| S:1401 E:1409 ||| VB
activity  ||| S:1409 E:1418 ||| NN
of  ||| S:1418 E:1421 ||| IN
these  ||| S:1421 E:1427 ||| DT
agents  ||| S:1427 E:1434 ||| NNS
in  ||| S:1434 E:1437 ||| IN
early  ||| S:1437 E:1443 ||| JJ
stages  ||| S:1443 E:1450 ||| NNS
of  ||| S:1450 E:1453 ||| IN
the  ||| S:1453 E:1457 ||| DT
disease ||| S:1457 E:1464 ||| NN
,  ||| S:1464 E:1466 ||| ,
patient  ||| S:1466 E:1474 ||| JJ
selection ||| S:1474 E:1483 ||| NN
,  ||| S:1483 E:1485 ||| ,
optimal  ||| S:1485 E:1493 ||| JJ
start  ||| S:1493 E:1499 ||| NN
time  ||| S:1499 E:1504 ||| NN
of  ||| S:1504 E:1507 ||| IN
the  ||| S:1507 E:1511 ||| DT
adjuvant  ||| S:1511 E:1520 ||| JJ
treatment ||| S:1520 E:1529 ||| NN
,  ||| S:1529 E:1531 ||| ,
and  ||| S:1531 E:1535 ||| CC
finally ||| S:1535 E:1542 ||| RB
,  ||| S:1542 E:1544 ||| ,
the  ||| S:1544 E:1548 ||| DT
optimal  ||| S:1548 E:1556 ||| JJ
length  ||| S:1556 E:1563 ||| NN
of  ||| S:1563 E:1566 ||| IN
treatment ||| S:1566 E:1575 ||| NN
.  ||| S:1575 E:1577 ||| .
